Literature DB >> 31122561

A Case of Primary Resistance to Gefitinib due to Novel Deletion-Insertion Mutation of EGFR Exon 19 in NSCLC.

Peiyi Xia1, Enjie Liu1, Pan Li1, Wencai Li1, Guozhong Jiang2.   

Abstract

Entities:  

Year:  2019        PMID： 31122561     DOI： 10.1016/j.jtho.2019.01.033

Source DB:  PubMed          Journal:  J Thorac Oncol        ISSN： 1556-0864            Impact factor:   15.609


× No keyword cloud information.
  2 in total

1.  Patients harboring uncommon EGFR exon 19 deletion-insertion mutations respond well to first-generation EGFR inhibitors and osimeritinib upon acquisition of T790M.

Authors:  Yurong Wang; Ruipan Zheng; Peizhu Hu; Ziheng Zhang; Shujing Shen; Xingya Li
Journal:  BMC Cancer       Date:  2021-11-13       Impact factor: 4.430

2.  Afatinib and osimertinib in lung adenocarcinoma harbored EGFR T751_I759delinsS mutation: A case report.

Authors:  Yueh-Fu Fang; Ping-Chi Liu
Journal:  Thorac Cancer       Date:  2021-11-02       Impact factor: 3.500
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.